Medikamentenvergleiche
Tirzepatide vs. Pioglitazone
Compare Tirzepatide (Mounjaro) vs Pioglitazone (Actos) for T2 diabetes. Dual GIP/GLP-1 agonist vs TZD: A1C, weight loss vs gain, CV risks, warnings.
Für diese Seite sind keine Vergleichsdimensionen verfügbar.
Klinischer Kontext
Type 2 diabetes patients comparing injectable dual incretin agonist tirzepatide against oral TZD pioglitazone for control, weight, and heart risks.
Fazit
Tirzepatide typically outperforms pioglitazone in A1C and weight loss for T2D but is injectable with GI effects.
Alle Medikamentenvergleiche